AUTHOR=Kunos Charles A. , Fabian Denise , Fredericks Tricia , Baldwin Lauren , Dietrich Charles , Miller Rachel W. , Ueland Frederick R. 

TITLE=Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1132135

DOI=10.3389/fonc.2023.1132135

ISSN=2234-943X

ABSTRACT=<sec><title>Introduction</title><p>The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy.</p></sec><sec><title>Methods</title><p>Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or &lt; 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control.</p></sec><sec><title>Results</title><p>Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or &lt; 10.0 g/dL groups, respectfully (P &lt; 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables.</p></sec><sec><title>Discussion</title><p>In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.</p></sec>